Is Estrogen Dominance Real? What's True, What's Sold, and What to Ask For

Is estrogen dominance real? No — not as a medical diagnosis. The biology beneath the label can be real: perimenopause can bring wide estradiol swings, occasional high peaks, and more cycles without ovulation, so progesterone may not rise as expected. But no validated ratio or test confirms “estrogen dominance.”

Partly, and the part that's real isn't the part being sold to you.

What changes the answer for your situation is whether you're still ovulating, how your bleeding has changed, whether you have a uterus, whether you use systemic estrogen, and what someone is asking you to buy. The physiology is defensible. The $499 panel is a different story, and we'll show you why using the labs' own instructions and prices.

The question you came with	The short answer
Is “estrogen dominance” a real diagnosis?	No. It has no dedicated ICD-10-CM code, agreed diagnostic criteria, or validated cutoff.
Is the biology underneath it real?	Yes. Estradiol can run high or swing sharply, ovulation can become unreliable, and estrogen can act on the uterine lining without enough progestogenic opposition. Those are different clinical questions.
Can a blood, saliva, urine, or DUTCH test confirm it?	No. Tests can measure hormones and metabolites. They cannot validate a label that has no accepted diagnostic threshold.
What is the number to know before buying a panel?	$168 for Labcorp OnDemand's separate $79 estradiol and $89 progesterone tests, or $499–$700 for DUTCH Complete, Plus, Cycle Mapping, and Cycle Mapping Plus on September 1, 2026. None diagnoses “estrogen dominance.”

---

This page is for you if

• Someone told you that you have estrogen dominance and you want to know whether that's a real thing.
• You're about to buy a hormone panel and you're doing one last check.
• You've been using a progesterone cream for months and nothing has changed.
• Your clinician waved the term away and you want to know who was right.
• Your symptoms show up on both the “high estrogen” and “low estrogen” lists and you're losing your mind about it.

This page is not for you if

• You have bleeding between periods, bleeding after sex, or any bleeding after 12 months without a period. Stop reading and arrange an evaluation. Skip to when bleeding needs a real evaluation.
• You're taking prescribed hormone therapy and thinking about stopping or replacing part of it. Do not do that based on anything you read online, here included.
• You want a symptom checklist rather than a verdict. Use the perimenopause symptoms checklist instead.

---

The one thing we can't do for you

We can't tell you whether you have estrogen dominance. Neither can anything you can buy, because there is no recognized threshold that returns a medically valid yes or no. What we can do is separate the underlying questions that clinicians can actually evaluate.

There's no calculator on this page that returns a diagnosis. No universal ratio to measure yourself against. No number that settles it. That's not us being cagey. It is the central finding.

If you came here for confirmation, we can't give it, and no honest test seller can manufacture it.

What we can give you is the thing nobody hands over: exactly what's documented and what isn't; exactly what each test measures, what it costs, and what it cannot establish; and the specific words that turn “my doctor dismissed me” into a visit where something real gets checked.

That last part is near the bottom, and it's the reason to keep this page open.

---

Before you go further

The right next step depends on your bleeding pattern, age, uterus status, symptoms, medication route, risk history, insurance, and state. A generic hormone label cannot resolve those decisions, and some situations need in-person care before any online intake.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

What we actually verified for this page

On September 1, 2026, we re-opened the primary commercial pages, current professional guidance, regulator records, drug labeling, and the research papers carrying the page's key numbers. We removed claims that could not survive that check.

We verified:

• Labcorp OnDemand's live $79 estradiol and $89 progesterone prices and its separate collection-timing instructions.^[1][2]
• All eight prices displayed in Precision Analytical's official DUTCH shop, including DUTCH Complete at $499, DUTCH Plus at $650, Cycle Mapping at $550, and Cycle Mapping Plus at $700.^[3]
• ACOG Clinical Consensus No. 6 on compounded menopausal hormone therapy and hormone testing. This is an ACOG document, not a joint ACOG/ASRM consensus.^[4]
• The current ICD-10-CM listing for E28.0, Estrogen excess, while confirming that “estrogen dominance” does not have its own code.^[5]
• FTC enforcement announcements from October 2007 and January 2008 concerning unsupported health claims for progesterone creams.^[6][7]
• Older and newer research on perimenopausal estradiol patterns, including Prior's pooled analysis, Hale's LOOP study, and SWAN's distinct estradiol trajectories.^[8][9][10]
• ACOG's April 2026 update on the initial evaluation of postmenopausal bleeding.^[11]
• The 48-week progesterone-cream study that produced the 32% inadequate endometrial opposition figure.^[12]
• The July 2025 DIM-and-estradiol-patch study, including the disclosed Precision Analytical affiliations.^[13]
• Current provider-stated pricing, insurance, state coverage, lab, and federal-beneficiary rules used in the limited care-routing section near the end.^{[14][15][16][17]}

What we did not do: diagnose anyone, run our own hormone panel, enroll in a clinic, receive treatment, or have a clinician review this page. Commercial facts are provider-stated unless we explicitly say otherwise. We date them so you can check them.

---

Seven estrogen-dominance claims, checked in one place

This is The HRT Index's claim audit: seven statements commonly bundled into one label, separated by what the evidence actually supports. The practical value is not another verdict. It is knowing which question to carry into a real appointment.

Claim	What the evidence supports	What it does not prove	The better next question
“Estrogen dominance is a recognized diagnosis.”	No dedicated ICD-10-CM code, professional diagnostic criteria, or validated threshold was found in the current sources audited.	That your symptoms are imaginary or that no underlying condition exists.	What named condition could explain my cycle, bleeding, and symptoms?
“Perimenopause means estrogen is simply low.”	Estradiol can rise, fall, and fluctuate sharply. Older pooled work found higher averages in selected comparisons; SWAN found several distinct trajectories rather than one universal pattern.[8][10]	That every woman has sustained high estrogen or needs estrogen lowered.	Is my pattern consistent with perimenopause, and does any other cause need ruling out?
“Low progesterone proves estrogen dominance.”	Progesterone normally rises after ovulation; anovulatory cycles do not produce the expected luteal rise.	A diagnosis from one untimed value, or a reason to self-prescribe progesterone.	Was the sample timed to ovulation, and would the answer change care?
“An estrogen-to-progesterone ratio confirms it.”	A ratio can be calculated mathematically if both values, units, sample type, and timing are known.	A medical diagnosis. No validated universal ratio cutoff separates “dominant” from “not dominant.”	What published cutoff are you using, for which sample type and cycle day?
“A saliva, dried-urine, or DUTCH panel can diagnose it.”	These tests can measure steroid hormones or metabolites using specified laboratory methods.	Diagnostic validity for “estrogen dominance.” ACOG says no FDA-approved salivary or urinary tests exist for steroid hormone measurement.[4]	What exact diagnosis will this panel confirm, and what changes if it is high, low, or normal?
“OTC progesterone cream protects the uterus.”	Some topical products deliver measurable progesterone.	Reliable endometrial protection. In one 48-week regimen, 32% of completers had proliferative or hyperplastic endometrial findings.[12]	What evidence supports this exact product, dose, route, and endometrial-protection plan?
“DIM clears excess estrogen.”	DIM can change urinary estrogen-metabolite profiles.	Symptom relief, treatment of a diagnosed disorder, or clinical benefit from “detoxing” estrogen.	Could this supplement interact with my prescribed estrogen or change how my results are interpreted?

This table is the page's whole argument in one screen. The label bundles together seven different claims. Only some of the biology survives when you pull them apart.

---

Is estrogen dominance real as a medical diagnosis?

No. “Estrogen dominance” is not a recognized diagnosis with agreed criteria. It has no dedicated ICD-10-CM code and no validated laboratory cutoff. A clinician can diagnose underlying problems — such as abnormal uterine bleeding, anovulation, PCOS, estrogen excess, or endometrial hyperplasia — but not confirm this umbrella label.

That's the flat answer. Now the useful part, because “it's not a diagnosis” is where every other page stops and where your actual problem starts.

What current sources can diagnose instead

Source or system	What it actually provides	Does it validate “estrogen dominance”?
ACOG perimenopause guidance	Evaluation based mainly on age, symptoms, and menstrual-cycle changes; hormone testing is usually unnecessary for identifying perimenopause.[18]	No diagnostic criteria or cutoff.
ACOG abnormal-bleeding guidance	A pathway for evaluating bleeding patterns and deciding when imaging or endometrial sampling is needed.[19]	No. It evaluates the bleeding, not the label.
ICD-10-CM	E28.0, Estrogen excess, plus separate codes for menstrual and endometrial diagnoses.[5]	No code for “estrogen dominance.” E28.0 is a different diagnosis, not a synonym.
US Department of Veterans Affairs Whole Health Library	A patient-education page that uses “estrogen dominance” for estrogen high relative to progesterone.[20]	No validated ratio, threshold, or diagnostic protocol.

That last row is why this question feels so slippery.

But you saw it on a government website

You probably did. The VA's Whole Health Library uses the phrase and describes several possible contributors. That means a federal patient-education page recognizes the vocabulary. It does not turn the phrase into a standardized diagnosis.^[20]

A patient-education page and a diagnostic standard are different documents. Patient education can use the words people arrive with. A diagnostic standard has to define who qualifies, how the condition is confirmed, what separates it from look-alikes, and what result changes treatment.

The VA page describes an idea. It does not supply those criteria.

When you see the term on a reputable site, that distinction matters: familiar language is not the same thing as a validated diagnosis.

What “not a diagnosis” does and doesn't mean

It does not mean: your symptoms are imaginary, you were stupid to believe the label, your body is fine, or nothing is happening.

It does mean: the phrase cannot carry a workup by itself. There is no accepted “estrogen dominance” test to order, no diagnostic threshold to apply, and no standard treatment protocol attached to the label.

So the conversation often ends, and you leave feeling dismissed.

That is the actual mechanism behind “my doctor didn't take me seriously.” Sometimes the clinician took you seriously and had nothing medically usable to do with the word. We'll fix the word later on this page.

---

Where did the term come from, and who profits from it?

John R. Lee, MD, said he coined “estrogen dominance” and used it to describe estrogen's effects when progesterone was relatively insufficient. The phrase spread through his 1990s books and a progesterone-cream market that had a direct commercial reason to teach women the framework. That origin does not disprove the biology. It does explain the sales architecture.

Lee's own site credits him with coining the phrase. The same site says his menopause book spread largely by word of mouth and through progesterone-cream manufacturers that used it to educate customers about why they were buying cream.^[21][22]

Read that once more.

The term was distributed in part by companies selling the product it pointed toward. That is not a conspiracy theory. It is how Lee's own site tells the story.

A peer-reviewed review later described the same commercial pattern: broad disease claims were attached to “bioidentical” hormones, and saliva testing could become a tool for persuading consumers to start hormones or use higher doses.^[23]

The part Lee got right

We're not going to sneer at him, and we're not going to sneer at the women or practitioners who still use his framework. That would be both unkind and lazy.

Midlife medicine spent years flattening a complicated transition into “estrogen deficiency.” Lee pushed back. He insisted that ovulation and progesterone mattered, and that women's midlife symptoms deserved a better explanation than a shrug.

The problem was not noticing something.

The problem was turning a useful observation into a label with no criteria, then letting that label become a permanent product category.

What regulators actually did

This is the most concrete evidence that the commercial side went too far.

Agency	Date	Claims at issue	Verified outcome
Federal Trade Commission	October 2007	Online sellers promoted “natural progesterone” creams for major health benefits without adequate substantiation.	The FTC filed complaints against seven sellers; six agreed to orders restricting unsupported claims.[6]
Federal Trade Commission	January 2008	A seller claimed progesterone creams could prevent or treat osteoporosis, reduce estrogen-related endometrial-cancer risk, and avoid breast-cancer risk.	The seller settled and agreed to restrictions on unsupported health claims.[7]

The FTC's consumer-protection director summarized the problem in six words: the companies made claims “they just couldn't prove.”^[6]

Those cases do not establish that every topical progesterone product is inert. They establish something narrower and more important: a seller cannot leap from “contains progesterone” to disease-prevention claims without evidence.

That is the same leap to watch for now.

---

What's actually happening in your body?

The clinically useful mechanism is not “estrogen dominance.” It is the interaction among ovulation, estradiol, progesterone, bleeding, medication exposure, and the uterine lining. When ovulation does not occur, there is no corpus luteum and no normal luteal progesterone rise. Estrogen can then stimulate the endometrium without adequate progestogenic opposition.

The short version:

Estrogen helps build the uterine lining. After ovulation, the corpus luteum normally produces progesterone, which changes and stabilizes that lining in preparation for a possible pregnancy.

No ovulation means no corpus luteum and no expected luteal progesterone rise.

That does not mean the body contains literally zero progesterone. It means the cycle did not produce the sustained post-ovulation rise that makes the second half of an ovulatory cycle different from the first.

Perimenopause can bring more cycles like that. The same transition can also bring breast tenderness, heavier or longer bleeding, bloating, disrupted sleep, and a mood you do not recognize. Those symptoms are real. They are not specific enough to prove one hormone direction.

And your estradiol result that month might still sit inside the laboratory's reference interval.

That is why normal-looking labs can feel like betrayal. The result may be accurate for the moment it was drawn and still fail to explain a moving cycle.

Translate the popular phrase into a clinical question

What you've been told	The question a clinician can actually evaluate	What makes the answer usable
“My estrogen is too high.”	Is estradiol unexpectedly elevated for my age, cycle phase, medication use, and clinical context?	Correct timing, units, reference range, symptoms, and medication history.
“My progesterone is too low.”	Did ovulation occur, and was progesterone measured at a meaningful time afterward?	Timing relative to ovulation matters because progesterone changes through the luteal phase.
“My hormones are unbalanced.”	Is this perimenopause, anovulatory bleeding, thyroid disease, pregnancy, PCOS, a medication effect, or another defined condition?	History, bleeding pattern, examination when needed, and targeted tests.
“My lining is too thick.”	Does imaging show abnormal endometrial thickness, and is tissue sampling indicated?	Ultrasound and, when indicated, pathology — not a symptom quiz.
“I feel estrogen spikes.”	Are my cycle changes consistent with the hormonal volatility described during the menopause transition?	Pattern over time matters more than one isolated value.

This is the reframe that should have been in your search results on day one:

The mechanism may be real. The label is too blunt to tell you which mechanism you have.

---

Is estrogen high or low in perimenopause?

Both can happen. Estradiol can rise, fall, and swing sharply during perimenopause, while ovulation becomes less reliable and progesterone may not rise normally in anovulatory cycles. “Estrogen is always high” is too simple. “Estrogen only declines” is too simple too. The defining pattern is volatility, not one permanent direction.

If you take one thing from this page, take this.

An older pooled analysis by Jerilynn Prior compared perimenopausal and premenopausal groups measured at the same study centers. In those selected comparisons, average estradiol was about 26% higher overall, with follicular-phase averages of 225 versus 175 pmol/L and premenstrual averages of 374 versus 300 pmol/L.^[8]

That finding is real. It is not the whole population story.

Longitudinal SWAN research later identified four distinct estradiol trajectories through the menopause transition rather than one universal decline or one universal high-estrogen pattern.^[10] Some women had higher-rising patterns before the final menstrual period; others followed flatter or declining paths.

So the strongest defensible sentence is not “perimenopausal estrogen is high.”

It is this:

Perimenopausal estradiol can be unusually high in some cycles, low in others, and far less predictable than it was before.

Higher peaks can be real. Low-estrogen symptoms can be real. Both can happen to the same woman at different points in the transition.

What are LOOP events?

In a typical ovulatory cycle, estradiol rises before ovulation, falls, and then has a smaller luteal-phase rise while progesterone is elevated. In some perimenopausal cycles, a new wave of follicular activity produces another unusually large estradiol rise during the luteal phase. Researchers call this a luteal out-of-phase, or LOOP, event.^[9]

In Hale and colleagues' observed perimenopausal cycles, roughly one-third showed LOOP events. Those cycles had lower luteal progesterone, higher early-cycle FSH, lower inhibin B, and were associated with unusually short or long cycle lengths.^[9]

Scope matters: that was a specific study sample, not proof that exactly one-third of every woman's cycles will behave this way.

But it is a documented pattern of high estradiol, lower luteal progesterone, and cycle disruption occurring together.

That's the thing you've been trying to describe.

So why did your labs come back normal?

Because a single blood draw catches one point on a curve that may change dramatically across the cycle and from one cycle to the next.

ACOG says hormone testing is usually not needed to identify perimenopause because age, symptoms, and menstrual changes generally tell the clinical story.^[18] SWAN's multiple estradiol trajectories explain why one result cannot stand in for the whole transition.^[10]

Your lab may not have been wrong.

It may have been a photograph of a roller coaster.

You're not imagining the weeks when you don't recognize yourself. What to do about them depends on your bleeding pattern, age, uterus status, symptoms, risk history, insurance, and state. Use Find My HRT Path to get a private care-routing result →
About 90 seconds. No email or account. The tool provides education and routing, not a diagnosis.

---

Can you have “estrogen dominance” when your estrogen is low?

*Yes — if someone is using “dominant” to mean estrogen is high relative to progesterone rather than objectively elevated. That is how the same person can be told she has low estrogen and “estrogen dominance” in the same week. The problem is that the phrase hides which claim is being made.*

There are two different models underneath one label:

Model	What it claims	Can it be measured?
Absolute estrogen excess	Estradiol is higher than expected for the person's age, cycle phase, medication exposure, and clinical context.	Potentially, with an appropriately interpreted test. One result still needs timing and context.
Relative “dominance”	Estradiol may be normal or low, but progesterone is lower still.	The two values can be measured, but the label cannot be diagnosed. There is no validated universal ratio cutoff.

This is why “high estrogen” and “low estrogen” symptom lists blur into each other. Sleep disruption, mood change, fatigue, irregular periods, and libido changes are not directional hormone meters.

A symptom quiz can tell you that your symptoms deserve attention.

It cannot tell you which hormone is high, which is low, whether ovulation occurred, or what treatment you need.

The question that sorts the claim

Stop asking only, “Am I estrogen dominant?”

Ask this:

“Are you saying my estradiol is objectively high, or that it is high relative to progesterone? What sample type, timing, units, and validated cutoff are you using — and what changes in my care?”

If the claim is objective estrogen excess, the person making it should be able to explain the reference range and context.

If the claim is a ratio, she should be able to show the validated cutoff for that exact sample type, unit convention, cycle timing, and patient population.

A good practitioner will answer plainly.

A sales funnel will get vague.

---

Can a blood, saliva, urine, or DUTCH test confirm estrogen dominance?

No. These tests can measure estradiol, progesterone, or hormone metabolites, but none can confirm “estrogen dominance” because no accepted diagnostic threshold exists. The problem is not that every measurement is fake. The problem is the jump from a real measurement to an invented diagnosis.

This is the section that can save you money, so we're going to be exact.

What Labcorp's timing instructions really show

Labcorp OnDemand currently lists:

Test	Price verified September 1, 2026	Labcorp's preparation instruction	What it can tell you
Estradiol (E2)	$79	If still menstruating, Labcorp recommends cycle day 3; if cycles are absent or irregular, it says testing can occur at any time.[1]	Estradiol concentration at that draw, interpreted against the assay's range and clinical context.
Progesterone	$89	Day 21 of a 28-day cycle, or seven days before the expected next period.[2]	Progesterone concentration at that draw; timing is intended to evaluate the luteal phase.

Different collection days do not make a same-draw ratio mathematically impossible. A laboratory can calculate a ratio from two values drawn at the same time. The real problems are:

1. 1. There is no validated universal ratio cutoff for “estrogen dominance.”
2. 2. The result changes with cycle day, ovulation timing, sample type, assay, and units.
3. 3. A ratio can look radically different depending on whether estradiol is reported in pg/mL or pmol/L and progesterone in ng/mL or nmol/L.
4. 4. A mathematically precise number can still be clinically meaningless.

Following Labcorp's separate standalone instructions would mean two collection dates and $168 in listed test prices. That may be appropriate when a clinician has two defined questions. It still does not create a diagnostic test for estrogen dominance.

Current official DUTCH prices

Precision Analytical's official shop displayed eight products on September 1, 2026:^[3]

Official listing	Published price	What the price does not buy
DUTCH Complete	$499	A validated diagnosis of estrogen dominance
DUTCH Plus	$650	A validated diagnosis of estrogen dominance
DUTCH Cycle Mapping	$550	A validated diagnosis of estrogen dominance
Cortisol Awakening Response	$299	A validated diagnosis of estrogen dominance
DUTCH Cycle Mapping & Complete Bundle	$650	A validated diagnosis of estrogen dominance
DUTCH Cycle Mapping Plus	$700	A validated diagnosis of estrogen dominance
DUTCH Sex Hormone Metabolites	$399	A validated diagnosis of estrogen dominance
DUTCH Adrenal	$399	A validated diagnosis of estrogen dominance

These are the official-shop prices we could verify on the date above. Prices can change. The diagnostic limitation does not: none of these product names supplies a recognized cutoff for the label you searched.

What each testing route can and cannot do

Testing route	What is measured	A legitimate use	What it cannot establish
Serum estradiol	Estradiol in blood at one moment	A clinician-defined question involving ovarian function, amenorrhea, medication monitoring, or suspected hormone excess	“Estrogen dominance” from a symptom list or untimed number
Serum progesterone	Progesterone in blood at one moment	Evidence relevant to ovulation when timing and context are appropriate	A universal estrogen-to-progesterone diagnosis
Salivary steroid panel	Steroids in saliva	Research or specific laboratory contexts	Reliable tailoring of menopausal hormone therapy or a validated dominance diagnosis
Dried-urine hormone/metabolite panel	Urinary hormones and metabolites over the collection protocol	Pattern description or research questions when the method fits the question	Proof that symptoms are caused by “estrogen dominance”
Cycle-mapping panel	Repeated hormone or metabolite measurements across a cycle	A longitudinal pattern generated under that platform's method	A condition for which no accepted case definition exists

What ACOG says about saliva and urine testing

ACOG's 2023 Clinical Consensus on compounded menopausal hormone therapy says salivary testing does not provide an accurate or precise assessment for tailoring hormone therapy. It also states that there are no FDA-approved salivary or urinary tests for steroid hormone measurement and that most patients do not need ancillary serum testing to dose menopausal hormone therapy; symptom response usually guides treatment.^[4]

That statement needs two boundaries.

It does not mean urine or saliva can never be used in any research or specialty context.

It means you should not be sold a menopause regimen on the promise that a saliva or urine “balance” number can individualize hormones with clinical precision that has not been demonstrated.

Is the DUTCH test accurate?

“Accurate” is the wrong one-word question.

DUTCH uses laboratory methods to quantify hormones and metabolites. Peer-reviewed studies have compared dried-urine results with other collection methods and have reported analytical relationships.^[24][25]

But analytical validity and diagnostic validity are not the same thing.

• Analytical question: Can this method measure the compounds it says it measures with acceptable repeatability and correlation?
• Diagnostic question: Does a specific result accurately identify a recognized condition and distinguish people who have it from people who do not?
• Clinical-utility question: Does using the result improve treatment decisions or outcomes?

Evidence supporting the first question does not automatically answer the second or third.

Several DUTCH-method studies were authored by people affiliated with Precision Analytical. That does not erase the data; disclosed affiliation is not misconduct. It means independent replication and the exact claim being made deserve attention.

The fair verdict is:

DUTCH can produce a detailed hormone-metabolite report. It cannot diagnose “estrogen dominance,” and the report's clinical value depends on the defined question, the interpreting clinician, and whether the result will change care.

When a hormone or other targeted test is worth ordering

We're not anti-testing. Testing is useful when it answers a named question.

A clinician may reasonably order targeted testing when evaluating:

• pregnancy;
• thyroid disease;
• iron deficiency or anemia;
• elevated prolactin;
• primary ovarian insufficiency in someone under 40;
• PCOS or another endocrine disorder;
• unexplained amenorrhea;
• suspected hormone excess;
• medication monitoring when a result would change management;
• an atypical situation in which age, symptoms, and cycle history do not answer the clinical question.

For routine perimenopause recognition, ACOG says age, symptoms, and menstrual changes are usually more useful than hormone testing.^[18]

A 2025 BMJ analysis reached the same practical line: commercial hormone panels should not guide menopause therapy when the result will not change care.^[26]

Four questions before you pay for any panel

Screenshot these. Ask them before your card comes out.

1. 1. What exact diagnosis is this test evaluating? Not “balance.” A named condition.
2. 2. Is this sample type, method, and timing validated for that question?
3. 3. What cutoff are you using, in what units, and where was it validated?
4. 4. What changes in my care if the result is high, low, or normal?

A good clinician will welcome those questions.

A sales funnel built on an undefined diagnosis usually cannot answer all four.

Before you spend $499 on a panel that cannot answer the label, spend about 90 seconds on a tool built to answer the decision you actually face. Find My HRT Path asks about your symptoms, cycle, medication preferences, insurance, and state, then routes you toward online care or flags when in-person care should come first. No email or account is required to see the result.

---

Is unopposed estrogen the same as estrogen dominance?

No. “Unopposed estrogen” is a defined biological and clinical concept: estrogen stimulates the endometrium without adequate progestogenic opposition. “Estrogen dominance” is an umbrella label used for symptoms, high estradiol, low progesterone, ratios, or metabolism claims. One identifies a mechanism that can guide care. The other does not identify which problem you have.

The difference shows up most clearly in the uterus.

Your situation	The better question than “Am I estrogen dominant?”
Still cycling with heavy, long, or irregular bleeding	Am I ovulating, and what other causes of abnormal bleeding need to be evaluated?
Using systemic estrogen and you have a uterus	What is my endometrial-protection plan, and what evidence supports this exact regimen?
Using systemic estrogen after hysterectomy	Does the dose, route, and indication fit my symptoms and risk history?
Using low-dose vaginal estrogen	Is this local product appropriate for my symptoms, and what does its own labeling say?
Bleeding after menopause	What is causing the bleeding, and how quickly should it be evaluated?

One detail trips people up: low-dose vaginal estrogen is not automatically managed by the same rules as systemic estrogen. Absorption, labeling, dose, and endometrial considerations differ by product and patient. Do not add or remove progesterone based on a generic web rule; use the specific product and your clinician's plan. See our vaginal estrogen guide for that separate decision.

Also: unopposed estrogen does not have one magical billing code. Clinicians document the actual situation — medication exposure, abnormal bleeding, anovulation, hyperplasia, or another diagnosis.

---

What are your symptoms actually pointing to?

The symptoms sold as proof of estrogen dominance are real but nonspecific. Heavy bleeding, breast tenderness, bloating, irritability, fatigue, and broken sleep can occur during perimenopause, but they also overlap with thyroid disease, iron deficiency, fibroids, PCOS, medication effects, sleep disorders, and mood conditions. A symptom list can justify evaluation. It cannot name the cause.

We're calling these symptoms worth evaluating, not symptoms that prove estrogen dominance.

That difference is not semantic. One opens a workup. The other closes it too early.

Symptom	Often attributed online to	Other questions worth checking	The miss that matters
Heavy or long periods	“High estrogen”	Anovulation, fibroids, polyps, pregnancy-related causes, bleeding disorders, medications, endometrial disease	Iron deficiency or anemia can be both a result and a major reason you feel terrible.
Breast tenderness	Estrogen excess	Cycle timing, pregnancy, medication changes, benign breast conditions	New focal symptoms, a lump, skin change, or nipple discharge need their own evaluation.
Bloating or weight change	“Estrogen retention”	Sleep, diet, thyroid disease, medications, body-composition change through midlife	The symptom does not identify a hormone direction.
Brain fog or fatigue	Hormone imbalance	Sleep disruption, iron deficiency, thyroid disease, depression, medication effects, sleep apnea	“Hormonal” and “hormone-only” are not the same claim.
Anxiety, irritability, or low mood	Progesterone deficiency	Hormone-sensitive mood change, sleep loss, stress, psychiatric history, medication or substance effects	Severe symptoms or thoughts of self-harm need prompt professional help, not a supplement stack.
Hot flashes or night sweats	Both high and low estrogen, depending on the seller	Menopause transition, medication effects, thyroid disease, infection or other causes when the pattern is atypical	Vasomotor symptoms can track hormonal change and withdrawal, not a stable “excess” number.

“But I matched 9 out of 12 symptoms”

We know. And that feels like proof.

Here is the uncomfortable arithmetic: fatigue, poor sleep, mood change, weight change, bloating, headaches, and breast tenderness are common. A list built from high-prevalence symptoms will match a large share of the audience it targets.

That's not diagnosis.

That's how horoscopes work.

It does not mean your nine symptoms are fake. It means the list did not earn the right to name their cause.

---

When is estrogen actually a safety problem?

Chronic estrogen stimulation without adequate progestogenic opposition is a major risk factor for endometrial hyperplasia. The safety signal is not a wellness ratio. It is abnormal bleeding, systemic estrogen without an appropriate protection plan, or a tissue diagnosis that needs treatment. Persistent or postmenopausal bleeding deserves evaluation, not another cream.

This is the section we'd keep if we could keep only one.

Endometrial hyperplasia is an overgrowth of the uterine lining. Some forms have no atypia and carry lower risk. Atypical hyperplasia, also called endometrial intraepithelial neoplasia in current clinical language, is a different and more serious biopsy finding.^[27]

Progression risk should not be compressed into one catch-all percentage because atypia, follow-up duration, and cancer already present but discovered during definitive treatment are different findings. A National Cancer Institute study reported progression from atypical hyperplasia to carcinoma of 8% through four years and 28% through 19 years. Non-atypical hyperplasia was far less likely to progress.^[28]

Those are population findings about a biopsy diagnosis. They are not the odds that a woman with newly heavy periods has cancer.

For scale, the American Cancer Society estimated 68,270 new cancers of the uterine corpus and 14,450 deaths in 2026. Those totals include the far more common endometrial cancers and a smaller number of uterine sarcomas; they are not pure endometrial-cancer counts.^[29]

Do not label these “estrogen dominance” and move on

Arrange evaluation if you have:

• Any bleeding after 12 months without a period. ACOG's April 2026 guidance recommends both transvaginal ultrasound and endometrial tissue sampling at the initial evaluation for most patients with postmenopausal bleeding.^[11]
• Bleeding between periods.
• Bleeding after sex.
• Repeated periods lasting longer than seven days or bleeding that is much heavier than your usual pattern.
• New abnormal uterine bleeding at age 45 or older. ACOG recommends endometrial sampling as a first-line test in this age group.^[19]
• Bleeding while using systemic estrogen without a clear endometrial-protection plan when you have a uterus, or persistent bleeding after a regimen change.
• Bleeding heavy enough that you are changing a pad or tampon every hour for more than two hours, especially with chest pain, shortness of breath, dizziness, or lightheadedness. Seek urgent or emergency care.^[19]

The real risk was never the idea

Here is the honest reframe, and it is the opposite of a cheap debunking article.

The danger was never that women started thinking about progesterone.

The danger is going unsupervised — treating a changing bleeding pattern with an internet cream for two years while nobody evaluates the lining.

The BMJ analysis described the same failure mode: commercial panels can become justification for compounded hormones or supplements without adequate clinical support, including regimens that may not provide sufficient endometrial protection.^[26]

Inadequate protection.

That's the risk.

Not the concept. The unmonitored product bought on the strength of it.

---

Does progesterone cream fix estrogen dominance?

No OTC or compounded transdermal progesterone cream should be assumed to correct “estrogen dominance” or protect the uterine lining. The most important evidence is not whether cream raises a measurable level. It is whether the exact regimen reliably opposes estrogen at the endometrium. One 48-week study found inadequate opposition in 32% of completers.

This is where the stakes get concrete.

The 32% study

The finding comes from Vashisht and colleagues. In the study, postmenopausal women used 1 mg transdermal estradiol plus 40 mg transdermal natural progesterone cream daily. Fifty-four women enrolled and 41 completed 48 weeks. At the end, 32% of completers had proliferative or hyperplastic endometrial findings, evidence of inadequate opposition under that regimen.^[12]

Nearly a third.

Doing what the regimen asked.

For almost a year.

This does not prove every progesterone cream fails at every dose. It proves you cannot look at the word progesterone on a cream and assume the uterine lining is protected.

That assumption is the dangerous part.

A wild-yam cream may not contain progesterone at all

Wild yam contains diosgenin, a plant compound used as a starting material in laboratory steroid manufacture. In a randomized trial, topical wild-yam cream did not raise measured serum or salivary progesterone and did not meaningfully improve menopausal symptoms over placebo.^[30]

A wild-yam cream marketed for “hormone balance” is not automatically a progesterone product. Check the actual ingredient and prescription status, not the front-label story. Our wild-yam cream guide covers that distinction.

Prescription progesterone is a different conversation

Do not let this section talk you out of legitimate prescribed care.

FDA-approved oral micronized progesterone is a real prescription medication. The current PROMETRIUM label specifically indicates it for prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated-estrogen tablets, and for secondary amenorrhea.^[31]

That label wording is narrower than “approved with any estrogen in any patient.” Clinicians also use progesterone in other evidence-based or off-label regimens, but the exact product, dose, route, schedule, and estrogen exposure matter.

An OTC cream, a compounded transdermal preparation, and an FDA-approved oral capsule are not interchangeable simply because all are discussed under the word progesterone.

If you use systemic estrogen and have a uterus, the question is not “Am I taking something progesterone-ish?”

It is:

“What is my documented endometrial-protection regimen, and what evidence supports this exact product, route, dose, and schedule?”

---

Do “estrogen detox” supplements like DIM work?

DIM changes estrogen metabolism and can alter urinary estrogen-metabolite profiles. What has not been established is that it treats “estrogen dominance,” improves menopause symptoms, or produces a clinical benefit by “detoxing” estrogen. A 2025 study also raises a practical interaction question for women using transdermal estradiol patches.

If you're taking DIM and prescribed estrogen, read this section carefully.

A July 2025 study in Menopause used a retrospective database of 1,458 results from postmenopausal women using transdermal estradiol patches. Of those, 108 reported concurrent DIM use. The DIM group had statistically significant differences in several urinary estrogen metabolites and ratios.^[13]

That does not show that DIM harmed them.

It does not show that DIM helped them.

It shows an association in urinary laboratory profiles, not a proven change in symptoms, bone outcomes, cardiovascular outcomes, cancer risk, or overall treatment effectiveness.

The conflict disclosure matters — and so does the finding

The paper disclosed that its lead author was president and CEO of Precision Analytical and that the co-author was an employee of the company. Precision Analytical makes the DUTCH test.^[13]

Both facts belong on the page:

• The affiliation was disclosed.
• The study still passed peer review and asked a useful question.
• The data came from the company's own testing database.
• Independent replication and clinical-outcome research are still needed.

The practical takeaway does not require drama:

Tell your prescriber about DIM, indole-3-carbinol, or any “estrogen detox” supplement — especially if you use prescribed estrogen.

It belongs on your medication list, not in a separate mental category called “just a supplement.”

---

Does this mean you need progesterone?

Not automatically. A symptom list, low untimed progesterone value, or “dominance” label cannot determine whether progesterone is indicated, which product to use, or how it should be dosed. Progesterone or another progestogen is central in specific situations — most clearly when endometrial protection is needed — but the reason has to be named.

Situations where a progestogen may be central include:

• Systemic estrogen use with an intact uterus. Most women in this situation need an evidence-based endometrial-protection strategy.^[37] A progestogen is common, but approved alternatives and individualized regimens exist; the prescriber must name the plan.
• Biopsy-confirmed endometrial hyperplasia or EIN/atypical hyperplasia. Treatment depends on subtype, fertility goals, cancer risk, and specialist guidance.
• Clinician-diagnosed anovulatory abnormal uterine bleeding.
• Certain contraceptive or cycle-control plans.

Situations where progesterone may be discussed but is not automatically the answer:

• sleep or vasomotor symptoms;
• cycle regulation;
• premenstrual symptoms;
• fertility-related luteal assessment;
• a medication side effect after starting hormone therapy.

And one situation where a web page should never improvise: replacing a prescribed progestogen with an OTC or compounded cream.

If you use systemic estrogen and have a uterus, switching products on your own may leave the endometrium inadequately protected. Do not stop or substitute anything. Ask the prescriber whether your current regimen is adequate.

Can HRT itself make you feel “estrogen dominant”?

It can produce symptoms people put under that label.

Breast tenderness, bloating, headaches, or spotting after starting estrogen can be worth reporting. The explanation might be dose, route, timing, an expected early adjustment, the progestogen component, an unrelated cause, or bleeding that needs evaluation.

Those possibilities do not lead to the same fix.

Do not diagnose yourself from the symptom and add a supplement or cream to “rebalance” the prescription.

Message your provider.

That's the whole answer.

---

What should you ask for instead?

Swap the label for the mechanism and the timeline. “I think I have estrogen dominance” gives a clinician no accepted threshold to apply. “My cycles changed in March, I now bleed nine days, and I have spotting between periods” maps to a real evaluation. Specific observations move care forward.

This is the part we'd want if we were you.

It is also the part that can turn a five-minute brush-off into a useful appointment.

Use words that lead to an evaluable question

What you might say now	Why it stalls	Say this instead	What it opens
“I have estrogen dominance.”	No agreed case definition or test	“My cycle length changed from about 28 days to 18–45 days over the last six months.”	Perimenopause, pregnancy, thyroid, PCOS, medication, and bleeding assessment
“My estrogen is too high.”	Missing timing, units, reference range, and context	“This estradiol result was drawn on cycle day __ while I was taking __. What does it answer?”	Proper interpretation of the actual test
“My progesterone is too low.”	One value may be mistimed	“Was this measured at the right point after ovulation, and would repeating it change care?”	A legitimate ovulation or luteal question
“My hormones are unbalanced.”	Too broad to select a workup	“My worst symptoms are __, they occur on cycle days __, and they started in __.”	Pattern recognition and targeted differentials
“I'm worried about my lining.”	Useful concern, but still needs the bleeding facts	“I have bleeding between periods / after sex / after menopause. Does my endometrium need imaging or sampling?”	The safety-relevant pathway

ICD-10-CM includes E28.0, Estrogen excess.^[5] That does not make it a magic phrase to request or a substitute for clinical criteria. Codes document conditions a clinician has evaluated; they are not passwords that force a diagnosis.

The four sentences to say out loud

Rehearse these. They take twenty seconds and change the shape of the visit.

1. 1. “Here's what changed and when.” Give a month and year.
2. 2. “Here's my bleeding pattern.” Cycle lengths, number of bleeding days, heaviness, clots, and any bleeding between periods or after sex.
3. 3. “Here's everything I've tried.” Include prescriptions, creams, DIM, wild yam, and any hormone panel.
4. 4. “Given this pattern and my medication use, does my endometrium need to be evaluated?”

That fourth sentence is not a demand for a biopsy.

It is a specific safety question with an answer the clinician can explain.

What to bring

• At least three cycles of dates and flow, or every episode you have if cycles are no longer predictable.
• Symptom timing relative to the cycle. “Worst during the ten days before bleeding” is more useful than “I feel awful.”
• The complete lab report, including units, reference ranges, collection date, cycle day, and all hormone use.
• Every medication and supplement, including creams, pellets, DIM, DHEA, wild yam, and anything you normally omit because it feels “natural.”
• Your uterus and ovary history, including hysterectomy type, endometrial procedures, fibroids, PCOS, and prior hyperplasia.

You have the words now. The next question is who to say them to. Find My HRT Path matches your symptoms, bleeding pattern, medication preference, insurance situation, and state to a care route — and says when the right starting point is in-person care rather than a website.

---

What actually treats unopposed estrogen?

Treatment targets the documented situation, not an estrogen-to-progesterone ratio. The goals may be to protect the uterine lining, control abnormal bleeding, treat a diagnosed condition, provide contraception, or relieve menopause symptoms. The correct option depends on uterus status, age, bleeding, diagnosis, medication exposure, and risk history.

Option or pathway	What it can do	FDA status in the United States	The limitation that matters
Prescribed progesterone or another progestogen	Oppose estrogen at the endometrium in an evidence-based regimen	FDA-approved products exist for specific labeled indications. PROMETRIUM's label is described above; other products have their own labels.[31]	Product, route, dose, and schedule are not interchangeable.
Levonorgestrel-releasing IUD	Provide contraception and reduce heavy menstrual bleeding with certain products	FDA approval varies by product; Mirena is approved for contraception and for heavy menstrual bleeding in users who choose it for contraception.[35]	Using an IUD as the progestogen component of menopausal hormone therapy is off-label in the US; duration and device matter.
Combined hormonal contraception	Suppress ovulation, regulate bleeding, and provide contraception	FDA-approved products exist for contraception	It is not menopausal hormone therapy and may be inappropriate with smoking at age 35 or older, migraine with aura, certain clot risks, or other contraindications.[36]
Menopausal hormone therapy with an endometrial-protection plan	Treat approved menopause indications with systemic estrogen when appropriate	Multiple FDA-approved estrogen and estrogen-progestogen products exist	Eligibility and risk-benefit assessment are individual; unexplained bleeding needs evaluation.
Diagnosis-specific treatment	Treat PCOS, thyroid disease, fibroids, anemia, hyperplasia, or another identified cause	Depends on the condition and product	“Hormone balance” is not a substitute for identifying the cause.
Compounded hormone preparation	Meet a specific need when an FDA-approved formulation cannot do so	The finished compounded product is not FDA-approved.	No FDA premarket review for safety, effectiveness, or quality; FDA warns quality problems can include too much or too little active ingredient. ACOG advises against routine use when an FDA-approved option meets the need.[4][32]

Compounded does not mean fake, useless, or automatically dangerous.

It means not FDA-approved as a finished product.

There can be legitimate reasons for compounding — such as a medically necessary formulation or excipient change that an approved product cannot provide. That is different from claiming a compounded cream is equivalent to, safer than, or more “natural” than an FDA-approved product.

We separate those categories because the distinction changes what evidence exists.

---

Who should not start with an online provider?

Online menopause care can be a reasonable starting point for many women. It is not the right starting point when the main problem may require a pelvic examination, urgent assessment, ultrasound, or endometrial sampling. Telehealth can triage and refer. It cannot perform those procedures through a screen.

We'd rather lose you to the right care than keep you on the wrong path.

Start with in-person or urgent care if you have:

• any bleeding after 12 months without a period;
• bleeding between periods or after sex;
• very heavy bleeding with dizziness, shortness of breath, chest pain, faintness, or weakness;
• new abnormal bleeding at age 45 or older;
• a known history of endometrial hyperplasia, EIN, or endometrial cancer;
• pregnancy or possible pregnancy;
• pelvic pain, a mass, fever, or symptoms that need a physical examination;
• absent or very irregular periods under age 40;
• a complex cancer, clotting, liver, or cardiovascular history that the online service cannot appropriately manage.

Medicare, Medicaid, and TRICARE rules are provider-specific

Federal-program rules differ by service. Here are the rules we could verify for the two services mentioned later on this page:

Service	Provider-stated federal-program rule verified September 1, 2026
Midi Health	Medicare is out of network, but Medicare beneficiaries may use Midi as self-pay patients and may not submit claims related to Midi visits, medications, or associated services. Midi says it cannot accept Medicaid or Medi-Cal patients, including as self-pay.[14]
Sesame	Sesame's Terms of Service require users to certify that they are not beneficiaries of a federal healthcare program such as Medicare, Medicaid, or TRICARE.[17]

Do not generalize one company's rule to every online clinic.

Check the exact service, your state, your plan, and whether the visit or medication would be billed.

---

If you want a clinician who will take the underlying problem seriously

This is an informational page, so the provider section stays late and narrow. The right choice is not the company willing to call the problem “estrogen dominance.” It is the care model able to take a bleeding history, review medication exposure, order a defined test when needed, and refer you for in-person evaluation when a screen is not enough.

Affiliate disclosure: The HRT Index may earn a commission from provider links that are marked as sponsored. Direct editorial links are not necessarily compensated. Commercial relationships do not change the factual standards on this page. See the full affiliate disclosure.

Midi Health — start here when commercial insurance and scheduled menopause care matter

The honest limitation first: Midi is not the lowest-cost cash-pay route, and it cannot accept Medicaid or Medi-Cal patients. Medicare beneficiaries may self-pay, but Midi says they cannot submit claims connected with Midi care.

Midi publishes self-pay visit prices of $250 for the first visit and $150 for follow-ups, says it is in-network with most PPO plans, and says coverage and cost sharing vary by plan.^[14] It reports availability in all 50 states.^[15]

Midi says it prescribes FDA-approved menopausal hormone therapies. It also separately offers Midi Custom Rx, a cash-pay line of compounded prescriptions.^[16]

Those categories need to stay separate:

• A prescription for an FDA-approved finished drug sent to a pharmacy is one medication path.
• A Midi Custom Rx compounded preparation is another.
• The compounded finished product is not FDA-approved.

Why Midi fits this page: the scheduled-visit model gives a clinician room to review bleeding, cycle history, prior treatments, and the need for targeted testing or referral.

Why it may not: the cash price is substantial, insurance is plan-dependent, and an online visit still cannot perform an ultrasound, pelvic examination, or biopsy.

→ Check Midi's current insurance and self-pay rules

Sesame — compare when you need a cash-pay marketplace or local in-person option

The honest limitation first: Sesame's federal-program restriction is unusually explicit. Its current Terms of Service require users to certify that they are not Medicare, Medicaid, or TRICARE beneficiaries.^[17]

Sesame's menopause page lists a $59-per-month subscription with video visits and basic lab work if a provider orders it. Medication costs are not included and depend on insurance and pharmacy.^[33] Lab-payment exceptions apply in several states, including New York, New Jersey, Rhode Island, and North Dakota.^[33]

Sesame's broader women's-health marketplace also lists video and in-person services, but the actual provider, location, price, and availability vary by market.^[34]

Why Sesame fits this page: a marketplace can be useful when the decision is not “Which hormone subscription?” but “Can I book the right kind of women's-health visit in my area?”

Why it may not: local inventory varies, a marketplace listing does not guarantee the exact procedure you need, and the federal-beneficiary restriction is a hard stop.

→ See current women's-health options and prices on Sesame

If neither route fits, use the best online HRT providers comparison or the routing tool rather than forcing yourself into the wrong model.

---

How we verified this page

This page is editorial research, not a clinical review. No clinician reviewed it. We name the source behind each medical, regulatory, price, and policy claim, date commercial facts, and remove claims we cannot verify strongly enough to publish.

We apply The HRT Index Verification Standard to every page: read every published price, separate FDA-approved from compounded medication, verify state availability and insurance language, and re-check on a fixed schedule — top providers monthly, the full roster quarterly.

We evaluate providers on five things, in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

For this page:

• Medical and regulatory claims were checked against ACOG, FDA labeling or FDA compounding information, FTC records, the CDC ICD-10-CM system, government cancer data, and peer-reviewed studies.
• Prices came from the seller's live page and are labeled with the date checked.
• Provider facts are provider-stated and date-verified, not claims that we personally received care.
• The article distinguishes a test's analytical ability to measure a compound from its ability to diagnose a condition.
• The article does not use an absence of a guideline mention as proof that an organization issued a formal rejection.
• The page contains no customer testimonial, efficacy testimonial, star rating, or invented score.

Why there are no customer testimonials here

A testimonial cannot establish whether “estrogen dominance” is a diagnosis, whether a hormone ratio is valid, or whether a product protects the endometrium.

Using a success story as proof of those claims would recreate the marketing problem this page documents.

So we did not do it.

What needs re-verification

• Monthly: Labcorp prices, official DUTCH prices, Midi pricing and insurance wording, Sesame pricing and federal-program terms.
• Quarterly: provider availability, included labs, medication-category disclosures, and internal links.
• On change: ACOG guidance, FDA labeling, FDA compounded-drug policy, ICD-10-CM codes, and major new clinical studies.

Read the full methodology and medical review policy.

---

Frequently asked questions

Is estrogen dominance real?

Not as a standardized medical diagnosis. It has no dedicated ICD-10-CM code, agreed diagnostic criteria, or validated cutoff. But several things people use the phrase to describe are real: estradiol can be high or erratic, ovulation can become unreliable, and the endometrium can be exposed to estrogen without adequate progestogenic opposition.

Do doctors believe in estrogen dominance?

The useful question is not whether a clinician “believes” the phrase. It is whether she evaluates the underlying problem. Describe your bleeding, cycle changes, medications, and symptom timing. Those facts map to real clinical questions even when the umbrella term does not.

Is estrogen dominance in the ICD-10-CM?

No dedicated ICD-10-CM code exists for “estrogen dominance.” E28.0, Estrogen excess, is a real code, but it is not interchangeable with the popular label. Separate codes cover abnormal bleeding, PCOS, and endometrial diagnoses.^[5]

Can a blood test show estrogen dominance?

No. A blood test can measure estradiol or progesterone at the time of collection. It cannot confirm a label with no validated diagnostic threshold. The result also has to be interpreted using cycle timing, medication exposure, units, assay range, symptoms, and the clinical question.

Can one blood draw produce an estrogen-to-progesterone ratio?

Yes, mathematically. But a number is not automatically a diagnosis: no accepted universal ratio cutoff defines estrogen dominance, and the value changes with units, sample timing, cycle phase, and method.

Why do Labcorp's estradiol and progesterone instructions use different days?

The tests answer different standalone questions. Labcorp recommends cycle day 3 for estradiol when menstruating and day 21 of a 28-day cycle — or seven days before the next period — for progesterone.^[1][2] Following both instructions means two draws and $168 in listed test prices. It still does not create an estrogen-dominance diagnosis.

Is the DUTCH test accurate?

DUTCH uses laboratory methods to measure hormones and metabolites, and published studies address analytical relationships with other collection methods.^[24][25] That does not validate “estrogen dominance” as a diagnosis or prove that using the panel improves menopause treatment. Ask which exact decision the result will change.

How much does a DUTCH test cost?

On September 1, 2026, Precision Analytical's official shop listed DUTCH Complete at $499, DUTCH Plus at $650, DUTCH Cycle Mapping at $550, and DUTCH Cycle Mapping Plus at $700. Other listed products ranged from $299 to $650.^[3] Prices can change.

Is estrogen high or low in perimenopause?

It can be either, and it can change quickly. Older pooled work found higher average estradiol in selected perimenopausal comparisons, while SWAN found four distinct estradiol trajectories.^[8][10] “Always high” and “always low” both flatten a variable transition.

Can you have “estrogen dominance” when estrogen is low?

Yes, under the relative-ratio meaning of the phrase: estrogen may be low in absolute terms but still higher relative to progesterone. That mathematical relationship does not establish a diagnosis. Ask what cutoff, units, sample type, and timing are being used.

Is unopposed estrogen the same as estrogen dominance?

No. Unopposed estrogen describes estrogenic stimulation of the endometrium without adequate progestogenic opposition. Estrogen dominance is a broad label that may refer to high estradiol, low progesterone, symptoms, ratios, or metabolism. The terms are not interchangeable.

Does progesterone cream help estrogen dominance?

No cream can be assumed to treat the label or protect the uterus. In a 48-week study of transdermal estradiol plus 40 mg transdermal progesterone cream, 32% of completers had proliferative or hyperplastic endometrial findings.^[12] Never replace prescribed endometrial protection with a cream based on a web claim.

Does wild-yam cream turn into progesterone in the body?

Topical wild-yam cream has not been shown to raise progesterone to a clinically meaningful level. In a randomized trial, it did not raise measured serum or salivary progesterone and did not meaningfully improve menopausal symptoms over placebo.^[30]

Does DIM lower estrogen?

DIM changes estrogen metabolism and can alter urinary metabolite profiles. That is not the same as proving symptom improvement or treatment benefit. A 2025 observational study found different urinary estrogen profiles among patch users who reported DIM use, but the clinical meaning remains uncertain.^[13]

Can you have estrogen dominance after menopause?

The label still has no validated criteria after menopause. Estrogen exposure can still matter because of medication use and estrogen production from peripheral tissues, and a woman with a uterus using systemic estrogen generally needs an appropriate endometrial-protection plan. Any postmenopausal bleeding needs prompt evaluation.

What's the difference between progesterone, progestogen, and progestin?

Progestogen is the umbrella category. It includes progesterone and synthetic compounds with progestational activity. Progesterone is the hormone produced by the body and is also available as prescription medication. Progestin usually refers to synthetic progestogens. These drugs can serve related roles but are not interchangeable dose for dose or product for product.

Should I stop my progesterone cream?

Do not decide that from this page. If you use a cream on your own, bring the product and dose to a clinician. If you use it as endometrial protection while taking systemic estrogen, do not stop or substitute anything on your own — arrange a review and ask whether the exact regimen provides adequate protection.

---

The bottom line

You weren't wrong.

You were given the wrong word.

Something real may be happening. Perimenopause can bring estradiol peaks, drops, and swings harder than most people are prepared for. Ovulation can become unreliable, so the expected luteal progesterone rise does not always arrive. Some observed cycles show a second estradiol surge during the luteal phase.

Your body can be doing something legitimately disruptive.

You noticed.

The label just cannot carry the diagnosis. There is no dedicated code, accepted case definition, validated cutoff, or panel — at any price — that can put “estrogen dominance” in your chart as a standardized answer.

What works instead is unglamorous and free:

Describe the bleeding.

Name the timeline.

Bring the actual report.

Ask what the result changes.

Ask whether your lining needs evaluation.

That's it.

That's the thing the $499 test was standing in for.

---

Still not sure which HRT program is right for you? Take our free 90-second matching tool.

→ Find My HRT Path

The tool provides educational routing, not a diagnosis or treatment plan. No email or account is required, and the live tool states that answers remain on the page. A licensed clinician makes all treatment decisions. Read the consumer health data privacy policy.

---

Related reading

• Perimenopause Symptoms Checklist
• Can You Take Progesterone Without Estrogen for Menopause?
• Perimenopause Irregular Periods: Treatment Options Online
• Vaginal Estrogen for Genitourinary Symptoms
• Wild Yam Cream for Menopause
• Best Online HRT Providers for Menopause

---

Sources

¹ Labcorp OnDemand. Estradiol (E2) Test. Price and preparation instructions accessed September 1, 2026.

² Labcorp OnDemand. Progesterone Test. Price and preparation instructions accessed September 1, 2026.

³ Precision Analytical. Official DUTCH Test Shop. All displayed product prices accessed September 1, 2026.

⁴ American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy: Clinical Consensus No. 6. November 2023.

⁵ Centers for Disease Control and Prevention, National Center for Health Statistics. ICD-10-CM Browser. 2026 code set; E28.0, Estrogen excess.

⁶ Federal Trade Commission. FTC Charges Seven Online Sellers of Alternative Hormone Replacement Therapy for Failing to Substantiate Health Claims. October 25, 2007.

⁷ Federal Trade Commission. Seller of Alternative Hormone Replacement Therapy Products Settles FTC Charges. January 10, 2008.

⁸ Prior JC. Perimenopause: The Complex Endocrinology of the Menopausal Transition. Endocrine Reviews. 1998;19(4):397–428.

⁹ Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical Estradiol Secretion and Ovulation Patterns Caused by Luteal Out-of-Phase Events. Menopause. 2009;16(1):50–59.

¹⁰ Tepper PG, et al. Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone during the Menopausal Transition. Journal of Clinical Endocrinology & Metabolism. 2012;97(8):2872–2880.

¹¹ American College of Obstetricians and Gynecologists. ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding. April 16, 2026.

¹² Vashisht A, et al. Bleeding Profiles and Effects on the Endometrium for Women Using Transdermal Oestradiol and Natural Progesterone Cream. BJOG. 2005;112(10):1402–1406.

¹³ Newman MS, Smeaton J. The Impact of 3,3′-Diindolylmethane on Estradiol and Estrogen Metabolism in Postmenopausal Women Using a Transdermal Estradiol Patch. Menopause. 2025;32(7):630–639.

¹⁴ Midi Health. Pricing and Insurance. Pricing and federal-program language accessed September 1, 2026.

¹⁵ Midi Health. Menopause Treatment. State-availability language accessed September 1, 2026.

¹⁶ Midi Health. Hormone Replacement Therapy and Midi Custom Rx. Medication-category disclosures accessed September 1, 2026.

¹⁷ Sesame. Terms of Service. Federal healthcare program certification language accessed September 1, 2026.

¹⁸ American College of Obstetricians and Gynecologists. Do I Need to Have Testing of My Hormone Levels during Perimenopause?.

¹⁹ American College of Obstetricians and Gynecologists. Abnormal Uterine Bleeding and Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women.

²⁰ US Department of Veterans Affairs, Whole Health Library. Estrogen Dominance.

²¹ John R. Lee, MD website. Estrogen Dominance. Used only for Lee's own account of the term.

²² John R. Lee, MD website. About John Lee, MD. Used only for the site's account of book distribution.

²³ Fugh-Berman A, Bythrow J. Bioidentical Hormones for Menopausal Hormone Therapy: Variation on a Theme. Journal of General Internal Medicine. 2007;22(7):1030–1034.

²⁴ Newman M, Curran DA. Reliability of a Dried Urine Test for Comprehensive Assessment of Urine Hormones and Metabolites. BMC Chemistry. 2021;15:18.

²⁵ Newman M, et al. Evaluating Urinary Estrogen and Progesterone Metabolites Using Dried Filter Paper Samples and Gas Chromatography with Tandem Mass Spectrometry. BMC Chemistry. 2019;13:20.

²⁶ Christakis MK, Roebotham T, Sterry S, Koshkina O. Menopause Misinformation Is Harming Care. BMJ. 2025;390:r1695.

²⁷ American College of Obstetricians and Gynecologists. Endometrial Hyperplasia and Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia.

²⁸ National Cancer Institute, Division of Cancer Epidemiology and Genetics. Study of Endometrial Hyperplasia Progression.

²⁹ American Cancer Society. Key Statistics for Endometrial Cancer. 2026 estimates.

³⁰ Komesaroff PA, et al. Effects of Wild Yam Extract on Menopausal Symptoms, Lipids and Sex Hormones in Healthy Menopausal Women. Climacteric. 2001;4(2):144–150.

³¹ DailyMed. PROMETRIUM — Progesterone Capsule Prescribing Information. Current labeling accessed September 1, 2026.

³² US Food and Drug Administration. Compounding and the FDA: Questions and Answers.

³³ Sesame. Online Menopause Treatment. Price, lab inclusions, medication-cost exclusion, and state exceptions accessed September 1, 2026.

³⁴ Sesame. Women's Health Services. Marketplace formats and availability accessed September 1, 2026.

³⁵ DailyMed. MIRENA — Levonorgestrel Intrauterine Device Prescribing Information. Current labeling accessed September 1, 2026.

³⁶ Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.

³⁷ American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause.